A Report of Disseminated Carcinomatosis of the Bone Marrow Originating from Transverse Colon Cancer Successfully Treated with Chemotherapy Using XELOX plus Bevacizumab

Naito, Masayasu; Yoshida, Yoichiro; Aisu, Naoya; Tanimura, Syu; Hoshino, Seiichiro; Tanaka, Toshihiro; Nimura, Satoshi; Tamura, Kazuo; Yamashita, Yuichi

doi:10.1159/000365001

Cited by 15 publications

(16 citation statements)

References 25 publications

(25 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In that study, 37 of the 40 cases (92.5%) were due to gastric cancer while one each was due to prostate, gallbladder, and ovarian cancer with unknown primary lesion, but no case of colorectal cancer was reported. A review of the literature revealed that DCBM in colorectal cancer is particularly rare and only 10 cases have been reported previously (Table 1) [8][9][10][11][12][13][14][15][16][17]. The average age of the patients was 61.0 years (men, 9 cases; women, 2 cases).…”

Section: Discussionmentioning

confidence: 99%

Treatment of Rectal Cancer-Induced Disseminated Carcinomatosis of the Bone Marrow with FOLFOX plus Cetuximab and Panitumumab

et al. 2020

View full text Add to dashboard Cite

Keywords Disseminated carcinomatosis of the bone marrow · Cetuximab · Colorectal cancer · PanitumumabAbstract Disseminated carcinomatosis of the bone marrow (DCBM) in colorectal cancer is an extremely rare complication with a poor prognosis. Here, we report a case of DCBM due to rectal cancer successfully treated with a combination of FOLFOX and an anti-epidermal growth factor receptor (EGFR) agent. The patient was a 38-year-old man diagnosed with rectal cancer with multiple bone and para-aortic lymph node metastases complicated by disseminated intravascular coagulation (DIC). He first recovered from DIC following cotreatment with FOLOX plus cetuximab; subsequently, the second attack was successfully treated with FOLFOX plus panitumumab. His initial condition was extremely poor, but he survived with two FOLFOX plus anti-EGFR regimens and died 333 days after introduction of chemotherapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Treatment of Rectal Cancer-Induced Disseminated Carcinomatosis of the Bone Marrow with FOLFOX plus Cetuximab and Panitumumab

et al. 2020

View full text Add to dashboard Cite

show abstract

“…In addition, it has been hypothesized that IL-3, IL-5 and other cytokines are involved in the differentiation and maturation of eosinophils (1,5,13,14). An association between bone marrow carcinogenesis and eosinophilia has been suggested (15), and although it is rare, previous studies have reported cases of bone marrow carcinogenesis accompanied by colon cancer (15,16). The patient in the present case underwent a blood transfusion to control bleeding caused by tumor hemorrhage and DIC, and then underwent emergency surgery; therefore, it was not possible to measure cytokine levels or perform bone marrow tests prior to surgery.…”

Section: Discussionmentioning

confidence: 99%

Impact of chemotherapy on eosinophilia-associated advanced rectal cancer: A case report and review of the literature

et al. 2016

View full text Add to dashboard Cite

Abstract. The present study reports a case of eosinophilia-associated rectal cancer that was successfully stabilized using chemotherapy, and reviews the mechanisms of eosinophilia and the importance of chemotherapy. A 65-year-old man, who had previously been diagnosed with suspected rectal cancer, presented with the chief complaint of melena. Eosinophilia, abnormal blood coagulation, and elevated carcinoembryonic antigen and carbohydrate antigen 19-9 tumor marker levels were observed, and the patient was subsequently diagnosed with advanced rectal cancer accompanied by multiple lymph node metastases that extended from the para-aortic lymph nodes to the left axillary lymph nodes. The complication of deep vein thrombosis was also observed. Tumor hemorrhage was exacerbated, and thus, Hartmann's procedure was performed. Pathological findings included poorly-to moderately-differentiated adenocarcinoma; however, no eosinophil infiltration was observed within the tumor. Following surgery, the eosinophilia and lymph node metastasis were exacerbated, and an oxaliplatin plus capecitabine chemotherapy regimen was initiated. The patient's eosinophil count and tumor marker levels normalized, and the lymph nodes decreased in size; however, re-enlargement of the lymph nodes was observed 6 months after surgery. The patient was then administered a chemotherapeutic regimen of irinotecan/fluorouracil/folinic acid + bevacizumab, and stable disease was maintained until pleural and peritoneal dissemination were observed at 22 months post-surgery. Following a rapid deterioration in condition, the patient succumbed to the disease at 23 months post-surgery. The present case indicates that although eosinophilia-associated colon cancer exhibits a poor prognosis, early chemotherapeutic intervention may improve this. IntroductionEosinophilia is known to cause complications in allergic disease and parasitic infections, and may occasionally cause complications in malignant tumors. Previous studies have indicated that eosinophilia-associated complications may arise not only in hematopoietic malignancies, but also in lung cancer (1), gastric cancer (2) and renal cell carcinoma (3); however, the mechanism has not been elucidated. Approximately 0.5-1.0% of cases of eosinophilia are associated with malignancies (2-4). Eosinophilia in solid malignancies is rarely reported,and there are a limited number of cases describing eosinophilia in rectal cancer. A number of previously reported cases have involved advanced cancers accompanied by metastases, and the majority have exhibited a poor prognosis. Peripheral hypereosinophilia is considered to be a poor prognostic sign, which is frequently associated with extensive metastatic disease (4-8) The present study reports the case of a patient with eosinophilia-associated advanced rectal cancer, which was successfully stabilized using chemotherapy. The possible mechanism underlying eosinophilia-associated complications in the present case and the importance of early chemotherapeutic intervention in treating ...

show abstract

“…In the contrary, colorectal cancer remains a rare cause of DCBM, with rectal cancer slightly more frequent. In one study, only 27 cases of colorectal cancer are reported, as an origin of DCBM, between 1984 and 2013 in Japan [1].…”

Section: Discussionmentioning

confidence: 99%

“…Various chemotherapy regimens are used for this purpose with different outcomes [4][5][6][7][8][9][10][11][12]. Although survival is improved in most cases, patients with colorectal cancer and DCBM do not survive more than 100 days [1]. Yoshida et al [13] report the early start of chemotherapy after surgery in patients with colorectal cancer and synchronous metastases, aiming at preventing tumor growth.…”

Section: Discussionmentioning

confidence: 99%

Disseminated Carcinomatosis of Bone Marrow Due to Sigmoid Colon Cancer

Konstantinidis¹,

Varsos²,

Sotirios³

2015

AJMCR

View full text Add to dashboard Cite

Introduction: Disseminated carcinomatosis of the bone marrow (DCBM) caused by colorectal cancer is rarely seen. DCBM is often accompanied with diffuse intravascular coagulation (DIC). Presentation Of Case: A 72-year-old male patient with a history of right nephrectomy three decades ago for referred benign disease, underwent sigmoid colon resection for cancer causing bowel obstruction. The preoperative evaluation revealed elevated values of CA 19-9 and PSA, with no metastatic lesions in abdominal CT. On eighth postoperative day, the patient developed fever with anemia and thrombocytopenia. Bone marrow examination revealed disseminated carcinomatosis caused by colon cancer. The patient deceased on the twenty seventh postoperative day due to the rapid progression of the accompanied disseminated intravascular coagulation. Discussion: Prognosis for patients with cancer who develop disseminated carcinomatosis of bone marrow (DCBM) is poor. Conclusion: In our case, the rapid deterioration of the patient gave us no option for adjuvant chemotherapy. The outcome was fatal. A 72-year-old male patient with a history of right nephrectomy for benign disease underwent sigmoid colon resection for bowel obstruction due to cancer. Tumor markers CA 19-9 and PSA were elevated, with no metastatic lesions in abdominal CT of admission. On eighth postoperative day, the patient developed severe anemia and thrombocytopenia. Bone marrow examination revealed disseminated carcinomatosis caused by colon cancer. The patient deceased on the twenty seventh postoperative day due to the rapid progression of the accompanied disseminated intravascular coagulation.

show abstract

A Report of Disseminated Carcinomatosis of the Bone Marrow Originating from Transverse Colon Cancer Successfully Treated with Chemotherapy Using XELOX plus Bevacizumab

Cited by 15 publications

References 25 publications

Treatment of Rectal Cancer-Induced Disseminated Carcinomatosis of the Bone Marrow with FOLFOX plus Cetuximab and Panitumumab

Treatment of Rectal Cancer-Induced Disseminated Carcinomatosis of the Bone Marrow with FOLFOX plus Cetuximab and Panitumumab

Impact of chemotherapy on eosinophilia-associated advanced rectal cancer: A case report and review of the literature

Disseminated Carcinomatosis of Bone Marrow Due to Sigmoid Colon Cancer

Contact Info

Product

Resources

About